Business
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology.
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n\nTramiprosate (ALZHEMED(TM)) Currently in Large Phase III Clinical Trials\nin North America and Europe\n\nLAVAL, QC, Nov. 2 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)\nis pleased to announce that Neurology, a worldwide, leading, peer-reviewed,\nmedical journal in the field of neurology, has published today an online\nversion of a publication on the Phase II clinical trial of tramiprosate \n(3-amino-1-propanesulfonic acid (3APS); ALZHEMED(TM)) conducted in\nmild-to-moderate Alzheimer's disease (AD) patients. Tramiprosate\n(ALZHEMED(TM)) represents a potential new class of disease-modifying agents\nand is Neurochem's investigational product candidate for the treatment of\nAlzheimer's disease. The results reported in the paper demonstrate that\nlong-term administration of tramiprosate (ALZHEMED(TM)) is safe, tolerated and\nreduces the level of amyloid (beta)42 (A(beta)42) in the cerebrospinal fluid\n(CSF) of AD patients. In addition, mean ADAS-cog(1) and MMSE(2) scores\nremained near baseline levels in the mild AD group over the 20 months of\nfollow-up.\nThe print issue of the publication will be available in the November 28,\n2006 issue of Neurology. The article entitled \"A phase II study targeting\namyloid (beta) with 3APS in mild-to-moderate Alzheimer disease\" will be\nhighlighted in the \"In This Issue\" section of the journal. An electronic\nversion of the article is already accessible online, and can be found at\nhttp://www.neurology.org under the \"Expedited E-pub\" section.\n\"This paper demonstrates the potential benefits of ALZHEMED(TM),\" said\nDr. Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown\nUniversity Medical Center, and principal investigator in the United States of\nthe ongoing Phase III clinical trial for tramiprosate (ALZHEMED(TM)). \"The\nALZHEMED(TM) program is at the forefront of therapeutic research in AD. The\nPhase II results show that ALZHEMED(TM) enters the central nervous system,\nwhere it reduces levels of A(beta). We look forward to concluding the ongoing\nNorth American Phase III clinical trial in January 2007, with the hope of\nintroducing a new therapeutic avenue for patients, and slowing the progression\nof the disease,\" he concluded.\nThis Phase II clinical trial sought to assess the safety, tolerability,\npharmacokinetic, and pharmacodynamic activi...